Efficacy and continuability of 675 mg fremanezumab administration over 2 years
Fremanezumab 675 mg quarterly dose effectively reduces headache frequency over an extended period and may facilitate medication cessation in patients who experience substantial recovery.
Authors
- Asami Moriya
- Shohei Yoshida (ORCID: https://orcid.org/0000-0001-8925-0927)
- Nobuyasu Yagi
- Noboru Imai (ORCID: https://orcid.org/0000-0002-8745-0391)
- Takashi Konishi (ORCID: https://orcid.org/0000-0003-1134-5445)
- Masahiro Serizawa
- Riéko Suzuki (ORCID: https://orcid.org/0000-0001-8445-1025)
- Masato Keicho
- Jun Kamimura
Institutions
- Shizuoka Red Cross Hospital (JP)
Publication Details
- Journal
- The Journal of Headache and Pain
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1186/s10194-025-01994-5
- Citations
- 3
- Primary Topic
- Sympathectomy and Hyperhidrosis Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.49